1.
JCPSP-Journal of the College of Physicians and Surgeons Pakistan. 2010; 20 (6): 423
em Inglês
| IMEMR
| ID: emr-98110
2.
Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia
JCPSP-Journal of the College of Physicians and Surgeons Pakistan. 2008; 18 (3): 176-178
em Inglês
| IMEMR
| ID: emr-100294
RESUMO
Imatinib mesylate is a BCR-ABL tyrosine kinase inhibitor used in the management of chronic myeloid leukemia. It is a safe and well-tolerated agent with a few manageable side effects. We are reporting a case of imatinib-related fatal bone marrow aplasia after complete cytogenetic response
Assuntos
Humanos , Masculino , Pirimidinas/efeitos adversos , Piperazinas/efeitos adversos , Proteínas Tirosina Quinases/antagonistas & inibidores , Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico
3.
JCPSP-Journal of the College of Physicians and Surgeons Pakistan. 2008; 18 (9): 576-577
em Inglês
| IMEMR
| ID: emr-102969
RESUMO
The spectrum of plasma cell neoplasm represents indolent conditions like Monoclonal Gammopathy of Undetermined Significance [MGUS] to more aggressive multiple myeloma and plasma cell leukemia. Non-secretory myeloma comprises less than 01% of this spectrum where serum protein electrophoresis and quantitative immunoglobulins remain essentially normal. We are presenting a case report of this rare variant involving the sternum of an adult male